{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T04:36:20Z","timestamp":1789706180565,"version":"4.0.1"},"reference-count":50,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2014,11,1]],"date-time":"2014-11-01T00:00:00Z","timestamp":1414800000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2014,11,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Malignant mesothelioma (MM), lung cancers, and asbestosis are hyperproliferative diseases associated with exposures to asbestos. All have a poor prognosis; thus, the need to develop novel and effective therapies is urgent. Vandetanib (Van) (ZD6474, ZACTIMA) is a tyrosine kinase inhibitor that has shown equivocal results in clinical trials for advanced non-small cell lung cancer. However, tyrosine kinase inhibitors alone have shown no significant clinical activity in phase II trials of patients with unresectable MM. Using epithelioid (HMESO) and sarcomatoid (H2373) human MM lines, the efficacy of tumor cell killing and signaling pathways modulated by Van with and without doxorubicin (Dox) was examined. Van alone reduced total cell numbers in HMESO MM and synergistically increased the toxicity of Dox in HMESO and H2373 cells. Most importantly, we identified two novel cell survival\/resistance pathways, ERK5 and cyclic AMP response element binding protein (CREB), that were inhibited by Van and Dox. After silencing of either ERK5 or CREB, significant decreases in cell numbers in the Dox-resistant sarcomatoid H2373 line were observed. Results suggest that a plethora of cell signaling pathways associated with cell survival are induced by Dox but inhibited by the addition of Van in MM. Data from our study support the combined efficacy of Van and Dox as a novel approach in the treatment of MM that is further enhanced by blocking ERK5 or CREB signaling cascades.<\/jats:p>","DOI":"10.1165\/rcmb.2013-0373tr","type":"journal-article","created":{"date-parts":[[2014,6,18]],"date-time":"2014-06-18T20:09:06Z","timestamp":1403122146000},"page":"595-603","source":"Crossref","is-referenced-by-count":11,"title":["Extracellular Signal-Regulated Kinase 5 and Cyclic AMP Response Element Binding Protein Are Novel Pathways Inhibited by Vandetanib (ZD6474) and Doxorubicin in Mesotheliomas"],"prefix":"10.1093","volume":"51","author":[{"given":"Mutlay","family":"Sayan","sequence":"first","affiliation":[{"name":"Department of Pathology, University of Vermont College of Medicine, Burlington, Vermont"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arti","family":"Shukla","sequence":"additional","affiliation":[{"name":"Department of Pathology, University of Vermont College of Medicine, Burlington, Vermont"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maximilian B.","family":"MacPherson","sequence":"additional","affiliation":[{"name":"Department of Pathology, University of Vermont College of Medicine, Burlington, Vermont"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sherrill L.","family":"Macura","sequence":"additional","affiliation":[{"name":"Department of Pathology, University of Vermont College of Medicine, Burlington, Vermont"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jedd M.","family":"Hillegass","sequence":"additional","affiliation":[{"name":"Department of Pathology, University of Vermont College of Medicine, Burlington, Vermont"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy N.","family":"Perkins","sequence":"additional","affiliation":[{"name":"Department of Pathology, University of Vermont College of Medicine, Burlington, Vermont"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joyce K.","family":"Thompson","sequence":"additional","affiliation":[{"name":"Department of Pathology, University of Vermont College of Medicine, Burlington, Vermont"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stacie L.","family":"Beuschel","sequence":"additional","affiliation":[{"name":"Department of Pathology, University of Vermont College of Medicine, Burlington, Vermont"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jill M.","family":"Miller","sequence":"additional","affiliation":[{"name":"Department of Pathology, University of Vermont College of Medicine, Burlington, Vermont"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brooke T.","family":"Mossman","sequence":"additional","affiliation":[{"name":"Department of Pathology, University of Vermont College of Medicine, Burlington, Vermont"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2014,11,1]]},"reference":[{"key":"2026021122270798100_bib1","first-page":"5334","article-title":"Asbestos causes stimulation of the extracellular signal-regulated kinase 1 mitogen-activated protein kinase cascade after phosphorylation of the epidermal growth factor receptor","volume":"56","author":"Zanella","year":"1996","journal-title":"Cancer Res"},{"key":"2026021122270798100_bib2","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1080\/10937404.2011.556047","article-title":"Pulmonary endpoints (lung carcinomas and asbestosis) following inhalation exposure to asbestos","volume":"14","author":"Mossman","year":"2011","journal-title":"J Toxicol Environ Health B Crit Rev"},{"key":"2026021122270798100_bib3","first-page":"935","article-title":"Pleural and peritoneal mesotheliomas in SEER: age effects and temporal trends, 1973-2005","volume":"20","author":"Moolgavkar","year":"2009","journal-title":"Cancer Causes Control"},{"key":"2026021122270798100_bib4","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1016\/j.ajpath.2012.12.028","article-title":"New insights into understanding the mechanisms, pathogenesis, and management of malignant mesotheliomas","volume":"182","author":"Mossman","year":"2013","journal-title":"Am J Pathol"},{"key":"2026021122270798100_bib5","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1038\/sj.bjc.6602602","article-title":"The realisation of targeted antitumour therapy","volume":"92","author":"Bicknell","year":"2005","journal-title":"Br J Cancer"},{"key":"2026021122270798100_bib6","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1038\/nrc1609","article-title":"ERBB receptors and cancer: the complexity of targeted inhibitors","volume":"5","author":"Hynes","year":"2005","journal-title":"Nat Rev Cancer"},{"key":"2026021122270798100_bib7","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/S0898-6568(01)00173-5","article-title":"Down-regulation of growth factor-stimulated MAP kinase signaling in cytotoxic drug-resistant human neuroblastoma cells","volume":"13","author":"Mattingly","year":"2001","journal-title":"Cell Signal"},{"key":"2026021122270798100_bib8","doi-asserted-by":"crossref","first-page":"3227","DOI":"10.1038\/sj.onc.1210414","article-title":"The ERK1\/2 mitogen-activated protein kinase pathway as a master regulator of the G1- to S-phase transition","volume":"26","author":"Meloche","year":"2007","journal-title":"Oncogene"},{"key":"2026021122270798100_bib9","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1080\/02699050500284218","article-title":"The extracellular signal-regulated kinase: multiple substrates regulate diverse cellular functions","volume":"24","author":"Yoon","year":"2006","journal-title":"Growth Factors"},{"key":"2026021122270798100_bib10","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1369\/jhc.5A6807.2006","article-title":"Phosphorylated extracellular signal-regulated kinases are significantly increased in malignant mesothelioma","volume":"54","author":"de Melo","year":"2006","journal-title":"J Histochem Cytochem"},{"key":"2026021122270798100_bib11","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1186\/1476-4598-9-314","article-title":"Blocking of ERK1 and ERK2 sensitizes human mesothelioma cells to doxorubicin","volume":"9","author":"Shukla","year":"2010","journal-title":"Mol Cancer"},{"key":"2026021122270798100_bib12","doi-asserted-by":"crossref","first-page":"2071","DOI":"10.1158\/1078-0432.CCR-12-3202","article-title":"Extracellular signal-regulated kinase 5: a potential therapeutic target for malignant mesotheliomas","volume":"19","author":"Shukla","year":"2013","journal-title":"Clin Cancer Res"},{"key":"2026021122270798100_bib13","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1002\/ijc.25763","article-title":"ERK2 is essential for the growth of human epithelioid malignant mesotheliomas","volume":"129","author":"Shukla","year":"2011","journal-title":"Int J Cancer"},{"key":"2026021122270798100_bib14","doi-asserted-by":"crossref","first-page":"12665","DOI":"10.1074\/jbc.270.21.12665","article-title":"Components of a new human protein kinase signal transduction pathway","volume":"270","author":"Zhou","year":"1995","journal-title":"J Biol Chem"},{"key":"2026021122270798100_bib15","doi-asserted-by":"crossref","first-page":"26563","DOI":"10.1074\/jbc.274.37.26563","article-title":"Activation of the protein kinase ERK5\/BMK1 by receptor tyrosine kinases. Identification and characterization of a signaling pathway to the nucleus","volume":"274","author":"Kamakura","year":"1999","journal-title":"J Biol Chem"},{"key":"2026021122270798100_bib16","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1038\/27234","article-title":"Bmk1\/Erk5 is required for cell proliferation induced by epidermal growth factor","volume":"395","author":"Kato","year":"1998","journal-title":"Nature"},{"key":"2026021122270798100_bib17","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1038\/sj.onc.1207163","article-title":"Src-dependent ERK5 and Src\/EGFR-dependent ERK1\/2 activation is required for cell proliferation by asbestos","volume":"23","author":"Scapoli","year":"2004","journal-title":"Oncogene"},{"key":"2026021122270798100_bib18","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1165\/rcmb.2007-0206OC","article-title":"HGF mediates cell proliferation of human mesothelioma cells through a PI3K\/MEK5\/Fra-1 pathway","volume":"38","author":"Ramos-Nino","year":"2008","journal-title":"Am J Respir Cell Mol Biol"},{"key":"2026021122270798100_bib19","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.lungcan.2012.02.022","article-title":"Exploratory analysis of activation of PTEN-PI3K pathway and downstream proteins in malignant pleural mesothelioma (MPM)","volume":"77","author":"Cedr\u00e9s","year":"2012","journal-title":"Lung Cancer"},{"key":"2026021122270798100_bib20","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1002\/cncr.25555","article-title":"Activation of the phosphoinositide-3-kinase and mammalian target of rapamycin signaling pathways are associated with shortened survival in patients with malignant peritoneal mesothelioma","volume":"117","author":"Varghese","year":"2011","journal-title":"Cancer"},{"key":"2026021122270798100_bib21","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1016\/j.jtcvs.2009.06.027","article-title":"Combined treatment with cisplatin and sirolimus to enhance cell death in human mesothelioma","volume":"139","author":"Hartman","year":"2010","journal-title":"J Thorac Cardiovasc Surg"},{"key":"2026021122270798100_bib22","doi-asserted-by":"crossref","first-page":"6080","DOI":"10.1038\/sj.onc.1208744","article-title":"Human and mouse mesotheliomas exhibit elevated AKT\/PKB activity, which can be targeted pharmacologically to inhibit tumor cell growth","volume":"24","author":"Altomare","year":"2005","journal-title":"Oncogene"},{"key":"2026021122270798100_bib23","doi-asserted-by":"crossref","first-page":"13021","DOI":"10.1074\/jbc.M709698200","article-title":"Mammalian target of rapamycin contributes to the acquired apoptotic resistance of human mesothelioma multicellular spheroids","volume":"283","author":"Barbone","year":"2008","journal-title":"J Biol Chem"},{"key":"2026021122270798100_bib24","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1165\/rcmb.2004-0355OC","article-title":"A novel in vitro model of human mesothelioma for studying tumor biology and apoptotic resistance","volume":"33","author":"Kim","year":"2005","journal-title":"Am J Respir Cell Mol Biol"},{"key":"2026021122270798100_bib25","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1038\/nm1052","article-title":"mTOR inhibition reverses Akt-dependent prostate intraepithelial neoplasia through regulation of apoptotic and HIF-1-dependent pathways","volume":"10","author":"Majumder","year":"2004","journal-title":"Nat Med"},{"key":"2026021122270798100_bib26","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1038\/nature02369","article-title":"Survival signalling by Akt and eIF4E in oncogenesis and cancer therapy","volume":"428","author":"Wendel","year":"2004","journal-title":"Nature"},{"key":"2026021122270798100_bib27","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1158\/0008-5472.CAN-06-0249","article-title":"Growth suppression of lung cancer cells by targeting cyclic AMP response element-binding protein","volume":"68","author":"Aggarwal","year":"2008","journal-title":"Cancer Res"},{"key":"2026021122270798100_bib28","first-page":"953","article-title":"Expression of transcription factor CREB1 in human breast cancer and its correlation with prognosis","volume":"18","author":"Chhabra","year":"2007","journal-title":"Oncol Rep"},{"key":"2026021122270798100_bib29","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.ccr.2005.02.018","article-title":"The role of CREB as a proto-oncogene in hematopoiesis and in acute myeloid leukemia","volume":"7","author":"Shankar","year":"2005","journal-title":"Cancer Cell"},{"key":"2026021122270798100_bib30","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1146\/annurev.biochem.68.1.821","article-title":"CREB: a stimulus-induced transcription factor activated by a diverse array of extracellular signals","volume":"68","author":"Shaywitz","year":"1999","journal-title":"Annu Rev Biochem"},{"key":"2026021122270798100_bib31","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.2353\/ajpath.2009.090400","article-title":"Activated cAMP response element binding protein is overexpressed in human mesotheliomas and inhibits apoptosis","volume":"175","author":"Shukla","year":"2009","journal-title":"Am J Pathol"},{"key":"2026021122270798100_bib32","first-page":"1546","article-title":"Antitumor effects of ZD6474, a small molecule vascular endothelial growth factor receptor tyrosine kinase inhibitor, with additional activity against epidermal growth factor receptor tyrosine kinase","volume":"9","author":"Ciardiello","year":"2003","journal-title":"Clin Cancer Res"},{"key":"2026021122270798100_bib33","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1007\/BF00685817","article-title":"Chemosensitivity and cytokine sensitivity of malignant mesothelioma","volume":"28","author":"Bowman","year":"1991","journal-title":"Cancer Chemother Pharmacol"},{"key":"2026021122270798100_bib34","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1002\/ijc.2910570423","article-title":"Doxorubicin retention and chemoresistance in human mesothelioma cell lines","volume":"57","author":"Isobe","year":"1994","journal-title":"Int J Cancer"},{"key":"2026021122270798100_bib35","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/j.lungcan.2009.08.007","article-title":"Results of systemic pemetrexed-based combination chemotherapy versus cytoreductive surgery and hyperthermic intraperitoneal cisplatin and doxorubicin on survival in malignant peritoneal mesothelioma","volume":"66","author":"Saxena","year":"2009","journal-title":"Lung Cancer"},{"key":"2026021122270798100_bib36","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1183\/09031936.00037310","article-title":"Valproate-doxorubicin: promising therapy for progressing mesothelioma. A phase II study","volume":"37","author":"Scherpereel","year":"2011","journal-title":"Eur Respir J"},{"key":"2026021122270798100_bib37","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1002\/ijc.25666","article-title":"Increased efficacy of doxorubicin delivered in multifunctional microparticles for mesothelioma therapy","volume":"129","author":"Hillegass","year":"2011","journal-title":"Int J Cancer"},{"key":"2026021122270798100_bib38","first-page":"3199","article-title":"Characterization of a human malignant mesothelioma cell line (H-MESO-1): a biphasic solid and ascitic tumor model","volume":"47","author":"Reale","year":"1987","journal-title":"Cancer Res"},{"key":"2026021122270798100_bib39","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1007\/s00280-008-0800-0","article-title":"A pharmacologic analysis of intraoperative intracavitary cancer chemotherapy with doxorubicin","volume":"63","author":"Van der Speeten","year":"2009","journal-title":"Cancer Chemother Pharmacol"},{"key":"2026021122270798100_bib40","first-page":"362","article-title":"The receptor tyrosine kinase inhibitor vandetanib activates Akt and increases side population in a salivary gland tumor cell line (A253)","volume":"41","author":"Fujishiro","year":"2012","journal-title":"Int J Oncol"},{"key":"2026021122270798100_bib41","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1158\/2159-8290.CD-13-0070","article-title":"Discovery of a novel ERK inhibitor with activity in models of acquired resistance to BRAF and MEK inhibitors","volume":"3","author":"Morris","year":"2013","journal-title":"Cancer Discov"},{"key":"2026021122270798100_bib42","doi-asserted-by":"crossref","first-page":"3527","DOI":"10.1158\/1078-0432.CCR-10-2504","article-title":"Targeting the BMK1 MAP kinase pathway in cancer therapy","volume":"17","author":"Yang","year":"2011","journal-title":"Clin Cancer Res"},{"key":"2026021122270798100_bib43","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1038\/bjc.2011.400","article-title":"Preclinical emergence of vandetanib as a potent antitumour agent in mesothelioma: molecular mechanisms underlying its synergistic interaction with pemetrexed and carboplatin","volume":"105","author":"Giovannetti","year":"2011","journal-title":"Br J Cancer"},{"key":"2026021122270798100_bib44","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1016\/j.ejca.2009.02.022","article-title":"Growth inhibition by tyrosine kinase inhibitors in mesothelioma cell lines","volume":"45","author":"Nutt","year":"2009","journal-title":"Eur J Cancer"},{"key":"2026021122270798100_bib45","first-page":"5242","article-title":"Inhibition of epidermal growth factor receptor signaling in malignant pleural mesothelioma","volume":"62","author":"J\u00e4nne","year":"2002","journal-title":"Cancer Res"},{"key":"2026021122270798100_bib46","doi-asserted-by":"crossref","first-page":"3924","DOI":"10.1158\/1078-0432.CCR-11-2041","article-title":"Vandetanib, an inhibitor of VEGF receptor-2 and EGF receptor, suppresses tumor development and improves prognosis of liver cancer in mice","volume":"18","author":"Inoue","year":"2012","journal-title":"Clin Cancer Res"},{"key":"2026021122270798100_bib47","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1006\/excr.2001.5262","article-title":"The role of ERK 1\/2 and p38 MAP-kinase pathways in taxol-induced apoptosis in human ovarian carcinoma cells","volume":"268","author":"Seidman","year":"2001","journal-title":"Exp Cell Res"},{"key":"2026021122270798100_bib48","doi-asserted-by":"crossref","first-page":"22128","DOI":"10.1074\/jbc.M800271200","article-title":"Oncogenic B-RafV600E inhibits apoptosis and promotes ERK-dependent inactivation of Bad and Bim","volume":"283","author":"Sheridan","year":"2008","journal-title":"J Biol Chem"},{"key":"2026021122270798100_bib49","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1007\/s10637-010-9572-6","article-title":"Vandetanib mediates anti-leukemia activity by multiple mechanisms and interacts synergistically with DNA damaging agents","volume":"30","author":"Macy","year":"2012","journal-title":"Invest New Drugs"},{"key":"2026021122270798100_bib50","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1097\/JTO.0b013e3182937317","article-title":"Vandetanib plus chemotherapy for induction followed by vandetanib or placebo as maintenance for patients with advanced non-small-cell lung cancer: a randomized phase 2 PrECOG study (PrE0501)","volume":"8","author":"Aisner","year":"2013","journal-title":"J Thorac Oncol"}],"container-title":["American Journal of Respiratory Cell and Molecular Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ajrcmb\/article-pdf\/51\/5\/595\/66807645\/ajrcmb_51_5_595.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ajrcmb\/article-pdf\/51\/5\/595\/66807645\/ajrcmb_51_5_595.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T03:27:40Z","timestamp":1770866860000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ajrcmb\/article\/51\/5\/595\/8467639"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,11,1]]},"references-count":50,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2014,11,1]]},"published-print":{"date-parts":[[2014,11,1]]}},"URL":"https:\/\/doi.org\/10.1165\/rcmb.2013-0373tr","relation":{},"ISSN":["1044-1549","1535-4989"],"issn-type":[{"value":"1044-1549","type":"print"},{"value":"1535-4989","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2014,11]]},"published":{"date-parts":[[2014,11,1]]}}}